These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37550187)

  • 61. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome.
    Trimech M; Letourneau A; Missiaglia E; De Prijck B; Nagy-Hulliger M; Somja J; Vivario M; Gaulard P; Lambert F; Bisig B; de Leval L
    Am J Surg Pathol; 2021 Jun; 45(6):773-786. PubMed ID: 33739791
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Nasr SH; Shanafelt TD; Hanson CA; Fidler ME; Cornell LD; Sethi S; Chaffee KG; Morris J; Leung N
    Ann Diagn Pathol; 2015 Jun; 19(3):130-6. PubMed ID: 25795422
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.
    Wang H; Yu X; Zhang X; Wang S; Zhao M
    Diagn Pathol; 2021 Jul; 16(1):59. PubMed ID: 34218814
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Gooden CE; Jones P; Bates R; Shallenberger WM; Surti U; Swerdlow SH; Roth CG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):129-135. PubMed ID: 27221715
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.
    Gao Q; Roshal M
    Curr Protoc; 2022 Aug; 2(8):e503. PubMed ID: 35980134
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.
    Ritgen M; Lange A; Stilgenbauer S; Dohner H; Bretscher C; Bosse H; Stuhr A; Kneba M; Dreger P
    Blood; 2003 Mar; 101(5):2049-53. PubMed ID: 12411304
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
    Kojima K; Burger JA
    J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
    Eyre TA; Hess LM; Sugihara T; He D; Khanal M; Pagel JM; Walgren RA; B Abada P; Konig H; Roeker LE; Mato A
    Leuk Lymphoma; 2023 May; 64(5):1005-1016. PubMed ID: 36987650
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
    Muñoz J; Sarosiek S; Castillo JJ
    Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.
    Thangavadivel S; Zhao Q; Epperla N; Rike L; Mo X; Badawi M; Bystry DM; Phelps MA; Andritsos LA; Rogers KA; Jones J; Woyach JA; Byrd JC; Awan FT
    Clin Cancer Res; 2020 Dec; 26(23):6187-6195. PubMed ID: 32958702
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
    Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
    Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
    Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.